SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial with a safety run-in component will evaluate whether the addition of
pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the
progression-free survival for patients with recurrent or new second primary Head and Neck
Squamous Cell Carcinoma (HNSCC).